The short version
- Why people research itRetinal ageing and visual function; the eye-specific bioregulator.
- What the evidence isNo randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
- What to watchSudden vision loss or flashes.
How Visoluten works
The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern.
Khavinson-school organ peptide extracts. The claim is tissue specificity: a short peptide fraction from one organ is proposed to act on that same organ, restoring its protein synthesis toward a younger pattern by binding regulatory DNA sequences. The mechanism is coherent and the human evidence for it is thin outside the group that proposed it.
- Oral
On the goal map: Brain & pineal (Organ-specific bioregulation)
Research on Visoluten4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it.
Human clinical evidence
No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
No completed human trial
Correlative data
The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
How the mechanism reads
The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern.
MechanisticOral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
Mechanistic
Sources
- Suetov AA. Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas. Vestnik Oftalmologii 2021 [Russian] · PMID 34726859
- Avetisov SE. Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture. Vestnik Oftalmologii 2019 [Russian] · PMID 30830079
- Malakhova AI. Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Vestnik Oftalmologii 2024 [Russian] · PMID 39569781
- Makashova NV, Vasil'eva AE, Morozova NE, Ronzina IA. Application of Retinalamin for the treatment of glaucomatous optic neuropathy. Vestnik Oftalmologii 2014 [Russian] · PMID 25306728
- Khvatova AV, Khlebnikova OV, Meshkova GI, Tarasenkov AO, Shchuvatova EL, Stromova OV. Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina. Vestnik Oftalmologii 2005 [Russian] · PMID 15881150
- Khavinson VKh. Inductive activity of retinal peptides. Bulletin of Experimental Biology and Medicine 2002 · PMID 12802458
- Khavinson VKh. Effects of peptides on proliferative activity of retinal and pigmented epithelial cells. Bulletin of Experimental Biology and Medicine 2003 · PMID 12937684
Visoluten safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Animal protein allergy: it is a retinal peptide fraction.
- Any untreated eye disease: a tissue extract is not a diagnosis or a treatment for glaucoma or macular disease.
- Pregnancy: an animal retinal extract is an undefined mixture with no gestation data.
- Under 18: retinal peptide signaling during eye growth is untested.
What’s expected
- Likely nothing felt; evidence is largely from the school that proposed it.
- Mild digestive upset.
- Any benefit would be slow.
Watch for
- Sudden vision loss or flashes.
- Eye pain with redness.
- Hives while using Visoluten.
- Blurred central vision.
Labs that tell you it’s working
- HbA1c (Hemoglobin A1c)
- Vitamin A
- Lipid Panel
- hs-CRP (C-Reactive Protein, High Sensitivity)
Visoluten (A-11) is an oral retina peptide fraction; the class claim is organ-specific action, and eye-health drivers are the measurable labs.
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Visoluten FAQ4 common questions
- Is Visoluten approved for human use?
- No. Visoluten is a research compound. No completed randomized human trial has given it yet.
- What is Visoluten researched for?
- Retinal ageing and visual function; the eye-specific bioregulator.
- Which labs show whether it's doing anything?
- HbA1c; Vitamin A; Lipid Panel; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Visoluten: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



